Welcome to the MimoVax project
European Team led by AFFiRiS AG is developing Alzheimer’s Vaccine
The EU-project MimoVax aims to cure patients through vaccination. This could be the first safe and efficacious treatment to halt progression of this crippling disease.
The cornerstone of the new vaccination strategy is the proprietary AFFITOM® technology of AFFiRiS AG, a biotech company based in Vienna. Compared to conventional approaches AFFITOM® allows fast, cost-effective and safe vaccine development.
The project started in October 2006 and ended in December 2011 with 2.4 M€ from the EC and a 2.0 M€ contribution by the participating SME. This 51 months STREP was coordinated by AFFiRiS AG and will concluded with a phase I clinical trial for the AD vaccine.
Supported by the EC’s FP6 through Contract No. LSHB-CT-2006-037702